FindTrial
Sign In

Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome

Use of 3,4-Diaminopyridine(3 4-DAP)in the Treatment of Lambert-Eaton Syndrome (LEMS)

Status
APPROVED_FOR_MARKETING
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT01825395
Acronym
3 4-DAP
Enrollment
Unknown
Registered
2013-04-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lambert Eaton Myasthenic Syndrome

Brief summary

To learn more about the effect of 3, 4-Diaminopyridine (3,4-DAP) on patient diagnosed with Lambert-Eaton myasthenic syndrome (LEMS).

Interventions

DRUG3, 4-Diaminopyridine

Sponsors

University of Colorado, Denver
Lead SponsorOTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 18 years or older, * Diagnosed with LEMS, * If female, have a negative pregnancy test, and * If premenopausal, be willing to practice an effective form of birth control during the study, * Tested and found by ECG not to have a prolonged QT syndrome, * Agree to have a second ECG at the time of peak drug effect, * Has understood and signed the Informed Consent.

Exclusion criteria

* Is known to have a sensitivity to 3, 4-DAP, * Has a history of: 1. past or current seizures, 2. cardiac arrhythmia, 3. hepatic, renal or hematologic disease, or 4. severe asthma, * Is believed by the investigator to be unable to comply with the protocol.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026